Can a Four-Minute Urine THC Screen Be Called 100% Accurate? What 100 Forensic Specimens Show

Short answer: A 2025 study of a portable fluorescence-based microfluidic urine test reported correct classification of all 100 selected forensic urine specimens—50 designated THC-metabolite positive and 50 negative—against its study reference. That is an impressive result within this selected panel, not evidence that the test has zero false positives or false negatives in every laboratory, workplace, roadside, or legal setting. The device screened for urinary THC-COOH, an excreted cannabis metabolite, at a study cutoff of 20 ng/mL; it did not measure active blood THC, observe driving, or diagnose impairment. These are the findings and limits of Jung and colleagues’ original 2025 analytical study.

What was tested—and what does a positive result actually mean?

The investigators developed a portable microfluidic fluorescence immunoassay intended to identify 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) in human urine. THC-COOH is formed after the body metabolizes THC and is subsequently eliminated, in part, through urine. A positive urine-metabolite result addresses whether the specimen generated an antibody response exceeding the assay’s decision threshold. It is not a measurement of THC’s psychoactive activity in the brain.

This distinction is particularly important when a rapid test is introduced as evidence in a driving, employment, probation, medical, or custody dispute. The result concerns the specified biological matrix, target, and testing time. It cannot establish how much cannabis was used, whether use occurred immediately before an incident, or whether the individual was functionally impaired at that incident. A separate explanation of biological matrices describes why urine, blood, oral fluid, and other specimens answer different questions.

The authors evaluated a screening device, not a replacement for every legally required definitive confirmation procedure. Its numerical output is a fluorescence-derived cutoff index. Its scientific significance depends on instrument calibration, specimen selection, metabolite recognition, interferences, cutoff behavior, and confirmation in the relevant application.

How did the four-minute microfluidic cartridge work?

A urine specimen was diluted with sample buffer at a reported 1:10 ratio; 60 µL of diluted sample was loaded into a cartridge. The reader measured fluorescent signals after approximately four minutes of flow and reaction. The portable instrument was described as roughly 127 × 206 × 150 mm and 1.5 kg. These are characteristics of the studied prototype configuration, not universally applicable specifications for other urine drug tests.

The test used a competitive immunoassay: as the amount of target metabolite increased, signal behavior at the test site changed in the opposite direction. A second fluorescence reference site helped normalize changes attributable to the specimen matrix. The resulting test-to-reference ratio (T/R) was processed relative to the defined cutoff to produce a cutoff index (COI). In this design, an index greater than 1 indicated a result above the chosen cutoff, while values on the other side of that boundary were classified negative.

That index is dimensionless: it is neither a direct chemical measurement in ng/mL nor a substitute for a full analyte-specific mass-spectrometric concentration. An index of 2 should not automatically be described as twice a patient’s urinary THC-COOH concentration or twice a person’s degree of intoxication. The study explicitly treated COI as a semi-quantitative signal, not a universal concentration-reconstruction formula.

Who contributed the 100 authentic specimens?

The investigators obtained 100 anonymized residual forensic urine specimens from the National Forensic Service in South Korea, intentionally divided into 50 designated positive and 50 designated negative samples. The report does not establish that these were a random sample of everyone tested at a roadside, workplace, or clinic. Nor should 100 specimens automatically be described as 100 independently enrolled and clinically evaluated drivers.

The comparator was an LC-MS/MS analytical workflow for urinary THC-COOH. That method had a reported calibration range of 5–200 ng/mL, with dilution and calculation of an appropriate factor for higher concentrations. Some positive specimens were also analyzed before and after enzymatic hydrolysis to compare the reader’s index with measurements of free versus hydrolyzable metabolite. Those comparisons were designed to investigate analytical behavior, not real-time drug effects.

The intentionally balanced 50/50 design is useful for examining classification against known reference categories. It does not measure the prevalence of cannabis exposure in a broader target population and cannot by itself establish a real-world positive predictive value. Predictive values change with prevalence, test specificity, analytical interferences, specimen characteristics, and how the positive reference classification is defined.

What were the actual positive, negative, and misclassification counts?

Figure 5 of the original publication shows no disagreements in the selected comparison panel. All 50 reference-positive specimens produced positive device classifications, and all 50 reference-negative specimens produced negative device classifications.

Observed 100% agreement is not the same as a proven population accuracy of 100%. With only 50 selected specimens on either side of the cutoff, events that are uncommon, concentration-dependent, or related to unusual medications and specimen chemistry may simply not appear. The paper does not report an independent blinded multicenter study or prospectively sampled all-comers roadside population establishing a zero-error rate.

The result also cannot be transported indiscriminately to another cutoff, laboratory procedure, product lot, reader software release, or target drug class. A reviewer should identify which protocol achieved the reported classifications and whether the actual case used the same method and validated conditions.

Why is the 20 ng/mL cutoff important?

The microfluidic assay used a 20 ng/mL urinary THC-COOH decision threshold. This is below the 50 ng/mL conventional screening threshold discussed by the authors. That difference does not mean one test is universally better in every context; a lower threshold can identify additional low-concentration specimens but requires appropriate evaluation of specificity, background response, and specimen validity.

A cutoff is an operational classification rule, not a physiological boundary at which a person becomes impaired. A screen-negative sample can still contain metabolite below the response threshold. A screen-positive sample may still require identification by a more chemically selective reference method before a consequential forensic conclusion is drawn. Moreover, a urinary metabolite cutoff cannot be equated to a statutory blood-THC concentration or an impairment limit.

The reader also displayed broad positive categories—approximately + at 20 ng/mL, ++ at 50 ng/mL, and +++ at 100 ng/mL—rather than a definitive individualized LC-MS/MS result. These are approximate threshold-associated assay categories, not certified quantitative reports of the true concentration in an unprocessed urine specimen.

Can the cutoff index be treated like an exact THC-COOH concentration?

No. The device normalizes test fluorescence against a reference signal to limit urine-matrix effects, and then relates that index to a threshold. The original investigators cautioned against converting the normalized index back into an absolute ng/mL estimate using a generic calibration curve, because doing so would reintroduce the very sample-specific matrix variation the normalization was designed to reduce.

There were concentration-response experiments covering standards from 0 to 1,000 ng/mL, but a broad calibration plot is not proof that a particular specimen’s index can be translated linearly and reliably into its exact concentration. Similarly, excellent association between an index and measured concentrations is not the same as close agreement of absolute values. Correlation measures how observations tend to move together; it does not establish numerical interchangeability between an immunoassay index and an LC-MS/MS report.

For a case involving a claimed specific metabolite concentration, the correct records are the actual quantitative laboratory method, its calibration and quality controls, specimen identification, reporting rules, and uncertainty. For the distinction between screening and chemical confirmation, see the site’s confirmatory drug testing guide.

What did hydrolysis reveal about free and glucuronidated THC-COOH?

Urinary THC-COOH occurs in both unconjugated and glucuronide-conjugated forms. The investigators compared their fluorescence index against LC-MS/MS analyses of the same 50 selected positive urine samples prepared either with β-glucuronidase treatment or without that treatment. Hydrolysis can release conjugated analyte for measurement as free THC-COOH under a validated procedure; analysis without hydrolysis focuses on the unconjugated fraction recovered by that method.

The index correlated more strongly with the hydrolyzed reference measurement (R² = 0.9471, p < 0.0001) than the nonhydrolyzed measurement (R² = 0.7303, p < 0.0001). The authors interpreted this pattern as consistent with antibody response encompassing free and glucuronidated urinary THC-COOH. It is meaningful analytical evidence, but it should not be mistaken for direct structural proof that every possible glucuronide is bound equally, or that no cross-reacting substance could ever affect an individual specimen.

One hydrolyzed sample had an exceptionally high reported THC-COOH concentration of 10,950 ng/mL. When that specimen was removed from the correlation calculation, the hydrolyzed association fell to R² = 0.7904 and the nonhydrolyzed association to R² = 0.5069, both reported with p < 0.0001. That change makes the influence of a high-concentration observation explicit. It also shows why a single headline R² is insufficient for judging precision across the range of concentrations likely to arise in casework.

Which primary results support the assay, and which caution against overclaiming?

These experiments address different dimensions of validity: classification in selected case specimens, relationship to a reference method, and reproducibility under controlled conditions. They should not be collapsed into a single number called “accuracy.” The repeatability and interoperator evaluations also involved multiple tests of prepared materials, not new independent human participants for each run.

What did the repeatability tests actually establish?

The authors challenged the device with prepared materials at three nominal concentrations: 50, 100, and 1,000 ng/mL. They assessed operator-to-operator, manufacturing-lot, instrument-to-instrument, and repeated-measurement variation. They reported between-operator, between-lot, and between-instrument coefficients of variation generally below 15%, and overall repeatability CVs of 11.7%, 12.9%, and 12.8% for the respective concentrations over the period described as ten days.

One-way analyses found no significant differences between the lot means or instrument means (reported p > .05). However, a high-concentration operator comparison was significant (p = .001) even though its between-operator CV was approximately 14%. Those findings are not contradictory: statistical detectability of a difference and magnitude of variation answer different questions. A nonsignificant difference is also not proof that two instruments or lots are equivalent under every operating condition.

Importantly, the prepared-material studies do not substitute for a full challenge against medications, specimen adulterants, extreme urine chemistry, borderline cutoff concentrations, storage conditions, and variation across collection sites. The degree to which those potential influences matter would depend on a separate validation matched to the actual use.

Could the device’s correlation with LC-MS/MS replace a confirmation procedure?

The findings support promising screening performance; they do not automatically displace analytical confirmation requirements. LC-MS/MS separates compounds chromatographically and detects selected mass transitions against validated calibrators and controls. The cartridge instead derives a normalized antibody-response index. Different analytical principles imply different questions about selectivity, potential cross-reactivity, matrix effects, and reporting certainty.

Even in this study, the researchers used a separate LC-MS/MS method to define and compare concentrations. That method employed an internal standard, a chromatographic column, controlled multiple-reaction monitoring, defined calibration concentrations and sample preparation procedures. The comparison does not turn the cartridge into an LC-MS/MS instrument.

For litigation or employment decisions, the next step depends on the governing policy, laboratory standard and particular issue being proved. A screen can guide whether to undertake specific additional testing; an assay result alone should not be characterized as final molecular confirmation or a validated clinical functional examination.

Does a positive urine THC-COOH result prove recent cannabis impairment?

No. THC-COOH is a metabolite measured in an excretory specimen. A positive screen supports a conclusion about the analytical target under the reported cutoff and conditions. It does not measure venous whole-blood parent THC, plasma parent THC, end-expiratory breath THC, or a person’s coordination, attention, reaction time, decision-making, or driving behavior at a claimed event.

A person may excrete THC-COOH after the psychoactive effects of a prior exposure have declined; the precise timeline varies and cannot be reconstructed reliably from one urine index. Conversely, a negative urine index at a given threshold does not exclude every recent or historic exposure. The observed four-minute assay response cannot be substituted for a dose estimate, numerical impairment prediction, or individualized account of a collision.

When facts require interpreting a specific specimen, the strongest approach is to identify its collection time, specimen identity, validity, known drug history, and the exact analytical method. The site’s specimen collection guidance outlines how handling and timing constrain later interpretation.

What are the most important limitations for legal or forensic use?

The headline specimen set was small and deliberately balanced. Only 50 reference-positive and 50 reference-negative urine samples were classified, without evidence that they represented all concentrations or interferents in a future target population. The authors did not validate an individualized impairment classifier, actual roadside safety outcome, or route-specific last-use prediction. No venous whole-blood THC concentration was directly measured as part of the cartridge’s principal diagnostic performance comparison.

The authors’ declared affiliations also matter in assessing independence: several investigators worked for a company developing related analytical technology. Such involvement does not negate the data, but it is a reason to seek external method replication, independent validation and underlying laboratory records before treating the findings as conclusive.

Urine dilution and sample validity are additional limits. The paper discusses creatinine normalization and integrity checks as useful extensions; it does not demonstrate a fully integrated validated creatinine-based specimen-validity module in the tested device. It is therefore unsound to assume that all deliberate or inadvertent dilution, substitution, or adulteration was necessarily detected by the prototype.

How should a forensic reviewer evaluate a four-minute urine THC result?

A review should begin with the instrument’s model and software version, precise lot and cartridge identifiers, quality-control and calibration records, the numerical COI and categorical threshold, analytical blank behavior, cross-reactivity evaluation, and any failed or repeated runs. Request the original instrument trace rather than relying only on a photographed “positive” display. Establish whether the specimen was diluted, how it was preserved and transported, and whether a validity test was performed.

Next identify the actual reference or confirmation method, its analyte list and specimen matrix, sample preparation with or without hydrolysis, calibration limits, identification criteria, and reporting threshold. Any claim that the device reported an exact ng/mL concentration should be checked against what the technology was validated to report. Finally, separate what the chemical evidence establishes from claims about dose, timing, psychomotor impairment, personal intent, or incident causation.

The Jung study demonstrates the feasibility of a rapid normalized microfluidic THC-COOH screen in a selected casework panel. It does not authorize a shortcut around validation, chemical specificity, uncertainty, or case-specific interpretation.

Frequently asked questions

Was the four-minute urine THC test really 100% sensitive?

It detected all 50 selected reference-positive urine specimens in this particular panel. That observed 50/50 result is not proof that future testing can never generate a false negative, especially at different cutoffs, concentrations or interference conditions.

How many negative urine samples were correctly identified?

All 50 selected reference-negative specimens screened negative, corresponding to 50/50 observed specificity in the study panel. It does not establish perfect specificity for every future sample or population.

What does the assay detect: THC or THC-COOH?

It targets urinary THC-COOH, an inactive carboxy metabolite of THC, rather than directly measuring psychoactive parent THC in blood. It is an exposure-marker screen, not a driver-impairment instrument.

Does a COI value of 3 mean three times the THC-COOH concentration?

No. COI is a normalized, unitless fluorescence decision index. The authors expressly limited its use to semi-quantitative categories and cautioned against translating it directly into an exact urine concentration.

Why did the study analyze urine both with and without hydrolysis?

The reference LC-MS/MS comparisons sought to distinguish free THC-COOH from hydrolyzable conjugated forms. The fluorescence index had a stronger reported association with hydrolyzed measurements, but those relationships do not alone establish universal chemical specificity.

Did the study validate a roadside impairment test?

No. The 100 real specimens were residual forensic urine samples; the investigation did not include contemporaneous on-road driving, a standardized clinical impairment reference, or a validated individual causal assessment.

Can the microfluidic test replace laboratory LC-MS/MS confirmation?

Its reported performance supports rapid preliminary screening under the tested conditions. Whether additional specific confirmation is required depends on the applicable standard and evidentiary question. The cartridge’s antibody signal is not equivalent to molecularly selective LC-MS/MS identification.

Primary scientific source and scope

Jung Y, Choi I, Bae H, et al. Semi-Quantitative On-Site Microfluidic Assay to Detect 11-Nor-9-carboxy-delta 9-Tetrahydrocannabinol (THC-COOH) in Urine. Sensors. 2025;25(23):7115. Original full primary research: DOI 10.3390/s25237115. All measurements and numerical findings discussed here refer to this specific original device evaluation, not a performance guarantee for other platforms or an individual forensic case.